Gert C. Scheper

Janssen (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index9.6kcitations117works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA regulation and disease(65), RNA and protein synthesis mechanisms(24), RNA Research and Splicing(21), Mitochondrial Function and Pathology(17), SARS-CoV-2 and COVID-19 Research(16)

Publications116 total

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial
Human Vaccines & Immunotherapeutics·2025· 2 citedOpen Access
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial
EClinicalMedicine·2025· 1 citedOpen Access
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial
Vaccines·2024Open Access
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16–17 Years of Age
Journal of the Pediatric Infectious Diseases Society·2024Open Access
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines
Journal of Thrombosis and Haemostasis·2024· 4 citedOpen Access
Review of: "Review: Human papillomavirus (HPV)"
2023Open Access
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Infectious Diseases·2022· 84 citedOpen Access
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
Vaccine·2022· 32 citedOpen Access
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
Human Vaccines & Immunotherapeutics·2022· 3 citedOpen Access
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
New England Journal of Medicine·2022· 246 citedOpen Access
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
2022· 6 citedOpen Access
LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
Open Forum Infectious Diseases·2021Open Access
RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults
2021
RCT Abstract - Ad26.COV2.S induces SARS-CoV-2 spike protein-specific cellular immunity and humoral immune responses that cover variants of concern
2021
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
2021· 23 citedOpen Access
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
New England Journal of Medicine·2021· 2.5k citedOpen Access
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
New England Journal of Medicine·2021· 1.2k citedOpen Access
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
2020· 141 citedOpen Access
Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma
Cancer Science·2020· 43 citedOpen Access
Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers
Biomolecules·2020· 39 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Marjo S. van der Knaap(29), Christopher G. Proud(12), Carola G.M. van Berkel(7), Jan C. Pronk(7), Barbara van Kollenburg(7), Ilja Boor(7), Emiel Polder(7), Harry O. Voorma(6), Raúl Estévez(6), Adri A.M. Thomas(6), Jerald Sadoff(5), Georgi Shukarev(5), Carla Truyers(5), Mathieu Le Gars(5), Hanneke Schuitemaker(5), Johan Van Hoof(5), Frank Struyf(5), Macaya Douoguih(5), Marianna Bugiani(5), Dan H. Barouch(4)